Amid a surge in demand for flu vaccinations, TTY Biopharm, one of Taiwan’s major vaccine suppliers, announced that all flu vaccine shipments have been delivered to healthcare institutions, supporting the nation’s epidemic prevention efforts. The company also hinted at the potential launch of new vaccine products this year. Additionally, with strong sales contributions from oncology and anti-infective products, TTY expects continued growth in its key overseas markets, particularly in the U.S. and Vietnam.

TTY also reported a preliminary after-tax profit of NT$1.196 billion for last year, with an earnings per share (EPS) of NT$4.81. Over the past three years, its cash dividend payout ratio has been close to 80%. Market estimates suggest that this year’s cash dividend per share will range between NT$3.6 and NT$3.9, translating to an implied cash dividend yield of approximately 5%.

Earlier, TTY’s management team projected high single-digit revenue growth for this year. In the domestic market, the company has consistently introduced new products in the vaccine and anesthesia/pain management sectors. Meanwhile, in overseas markets, Lipo-AB, a blockbuster anti-infective drug in the U.S., has been on the market for two years, with a steadily increasing market share. TTY also continues to expand its presence in Vietnam, having signed MOUs with more than three major medical institutions, with ongoing efforts to secure additional hospital partnerships.

Resource: 東洋今年新品續堆疊；海外市場再加溫